SPY333.25-1.32 -0.39%
DIA275.95+1.33 0.48%
IXIC10,860.47-150.51 -1.37%

SunTrust Robinson Humphrey Initiates Coverage On Fate Therapeutics with Buy Rating, Announces $25 Price Target

SunTrust Robinson Humphrey initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Buy rating and a $25 price target.

Benzinga · -

SunTrust Robinson Humphrey initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Buy rating and a $25 price target.